Ibuprofen decreases likelihood of altitude sickness, researchers find

March 20, 2012 in Medications

A new study led by Grant Lipman, M.D., an emergency medicine physician at Stanford Hospital & Clinics and a clinical assistant professor at the Stanford University School of Medicine, has found that ibuprofen, a widely available, over-the-counter drug, may help relieve acute mountain sickness, or altitude illness. The study will be published online March 20 in Annals of Emergency Medicine.

"A really nasty hangover" is how Grant Lipman, MD, describes the feeling of acute mountain sickness, and for good reason: Symptoms can include headache, fatigue, dizziness, nausea, vomiting and poor appetite.

More than 25 percent of the millions of Americans who travel to high elevations each year, often to hike, camp or ski, will suffer from this condition, also known as altitude illness. But a new study led by Lipman, an emergency physician at Stanford Hospital & Clinics and a clinical assistant professor at the Stanford University School of Medicine, has found that a widely available, over-the-counter drug may help.

Ibuprofen, an anti-inflammatory medication often used as a painkiller, was found to significantly reduce the incidence of altitude sickness in a double-blind, placebo-controlled trial of 86 men and women, according to the study, which will be published online March 20 in Annals of .

The findings could prove especially useful for recreationists who have weeklong vacations planned at high altitudes. "You don't want to feel horrible for 15 to 20 percent of your vacation," Lipman said. "Ibuprofen could be a way to prevent AMS in a significant number of the tens of millions of people who travel to high altitudes each year."

Acute mountain sickness can do more than just make life miserable: If left unrecognized or untreated, it can lead to high-altitude cerebral edema, an often-fatal swelling of the brain.

For the study, 58 men and 28 women traveled to an area of the White Mountains northeast of Bishop, Calif. They spent the night at 4,100 feet and were given either 600 milligrams of ibuprofen or a placebo at 8 a.m., before heading up the mountain to a staging area at 11,700 feet. There, they were given a second dose at 2 p.m. Then they hiked about 3 miles up to 12,570 feet, where they received a third dose at 8 p.m. before spending the night on the mountain.

Of the 44 participants who received ibuprofen, 19 (43 percent) suffered symptoms of altitude sickness, whereas 29 of the 42 participants (69 percent) receiving placebo had symptoms, according to the study. In other words, ibuprofen reduced the incidence of the illness by 26 percent.

The researchers also observed less severe symptoms overall in those who took the drug compared with those in the placebo group, but the reduction in severity was not statistically significant, based on the self-reporting questionnaire that was used.

At high altitudes, decreased atmospheric pressure means that each breath you take contains fewer oxygen molecules. However, the exact physiological mechanisms that lead to acute mountain sickness are not clearly understood. Some researchers think the condition occurs because a lack of oxygen to the brain causes it to swell with fluids. Ibuprofen may help to reduce that swelling.

Other medications are available to prevent mountain sickness — specifically, acetazolamide and dexamethasone — but they have downsides. "The safety profile of ibuprofen makes it more attractive then dexamethasone, which has been associated with hyperglycemia, adrenal suppression, delirium, depression, insomnia and mania," the authors note. "Acetazolamide's adverse effects of nausea, dizziness and fatigue are usually well-tolerated but can be as debilitating as acute ."

They add: "We suggest that availability alone makes ibuprofen an appealing drug for individuals who travel to . In addition, ibuprofen was effective when taken six hours before ascent, in contrast to acetazolamide, whose recommendations include that it be started the day before travel to high altitude."

The authors say that taking more than 600 mg of might "provide more robust prevention" but that the theoretical benefits of such a move would have to weighed against a possibly increased risk of gastrointestinal and kidney problems in people who may be dehydrated.

Provided by Stanford University Medical Center search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Medications created 8 hours ago | popularity 1 / 5 (1) | comments 0

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Medications created 9 hours ago | popularity 5 / 5 (1) | comments 0

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created May 22, 2013 | popularity not rated yet | comments 0


Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

Motion quotient: IQ predicted by ability to filter motion (w/ video)

A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...

Multiple research teams unable to confirm high-profile Alzheimer's study

Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.

Scientists discover molecule triggers sensation of itch

Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...

Researchers find common childhood asthma unconnected to allergens or inflammation

Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...

ACP issues recommendations for management of high blood glucose in hospitalized patients

High blood glucose is associated with poor outcomes in hospitalized patients, and use of intensive insulin therapy (IIT) to control hyperglycemia is a common practice in hospitals. But the recent evidence does not show a ...